
Compositions: Glimepiride IP 1 mg and 2 mg; Glimepiride BP 1 mg, 2 mg and 4 mg; SMEGLIP-1 and SMEGLIP-2.
Separate combination: Glimepiride 2 mg + Pioglitazone 15 mg + Metformin Hydrochloride 500 mg SR.
Usage: Management of type 2 diabetes alongside diet and exercise.
Category: Anti Diabetic Drugs
Therapeutic Category: Antidiabetic
SKU: Glimepiride Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Glimepiride Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
Glimepiride is an oral sulfonylurea antidiabetic medicine used to improve glycaemic control in adults with type 2 diabetes alongside diet and exercise. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter. The confirmed standalone products are film-coated glimepiride 1 mg, 2 mg and 4 mg tablets under the IP/BP standards shown below.
The separately supplied glimepiride/pioglitazone/metformin SR product is a different three-ingredient formulation, not a strength of glimepiride-only tablets.
Generic name: Glimepiride; CAS: 93479-97-1; Therapeutic class: Sulfonylurea antidiabetic; Dosage form: Film-coated tablet for confirmed standalone variants.
| Product / brand | Each tablet contains | Dosage form |
|---|---|---|
| Glimepiride Tablets IP 1 mg | Glimepiride IP 1 mg | Film-coated |
| Glimepiride Tablets IP 2 mg | Glimepiride IP 2 mg | Film-coated |
| Glimepiride Tablets BP 1 mg | Glimepiride BP 1 mg | Film-coated |
| Glimepiride Tablets BP 2 mg | Glimepiride BP 2 mg | Film-coated |
| Glimepiride Tablets BP 4 mg | Glimepiride BP 4 mg | Film-coated |
| SMEGLIP-1 | Glimepiride BP 1 mg; excipients q.s. | Film-coated |
| SMEGLIP-2 | Glimepiride BP 2 mg; excipients q.s. | Film-coated |
| Separate triple combination | Glimepiride 2 mg + Pioglitazone 15 mg + Metformin Hydrochloride 500 mg; excipients q.s. | Sustained-release |
Strength verification: 3 mg is mentioned in the proposed description but no 3 mg composition was supplied. Shelf life, packaging, tablet colour and exact pharmacopeial test limits must follow the registered product specification.
Manufacturing low-dose glimepiride tablets requires validated blending, tablet-weight control and content uniformity. Particle-size management and dissolution performance are relevant formulation considerations; specific micronization, granulation and colour-coding methods must be verified against the approved manufacturing dossier before being claimed for this product.
Appropriate quality controls include identification, assay, uniformity of dosage units, dissolution, related substances, packaging integrity and stability testing according to the applicable approved IP/BP specification. Do not assume fixed dissolution percentages or bioequivalence without batch or study documentation.
Glimepiride binds to sulfonylurea receptors associated with ATP-sensitive potassium channels in pancreatic beta cells, stimulating insulin secretion. It can reduce blood glucose even when glucose is already low and therefore carries a clinically important risk of hypoglycaemia. It is used in type 2 diabetes, alone or with other treatments as prescribed; it is not indicated for type 1 diabetes or diabetic ketoacidosis.
For export enquiries, product-specific certificates of analysis, packaging options, certificates and CTD/ACTD documentation should be confirmed for the relevant market and registered formulation. Regulatory approval in any country must not be assumed.
What strengths are documented?
Film-coated 1 mg and 2 mg IP/BP tablets, plus BP 4 mg, SMEGLIP-1 and SMEGLIP-2. A 3 mg formulation is not confirmed by the supplied compositions.
Is Glimepiride the same as Amaryl?
Amaryl is a brand of glimepiride. Pharmaceutical equivalence or bioequivalence for a particular product must be established separately.
Can it cause low blood sugar?
Yes, particularly with missed meals, strenuous exercise, alcohol, illness or interacting medicines.
Is the triple combination the same medicine?
No. It additionally contains pioglitazone and metformin and has separate prescribing precautions.
Use the exact dose and timing prescribed by a clinician, typically with breakfast or the first main meal. Dosing depends on blood-glucose monitoring, kidney/liver function, other medicines and the approved label. Do not change dose or substitute combination tablets without medical advice.
Store according to the approved pack label, protected from moisture and excessive heat. Keep out of reach of children.